MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
30.25
+0.27
+0.90%
Closed 19:58 07/07 EDT
OPEN
30.29
PREV CLOSE
29.98
HIGH
30.63
LOW
29.73
VOLUME
794.37K
TURNOVER
0
52 WEEK HIGH
31.74
52 WEEK LOW
8.03
MARKET CAP
3.80B
P/E (TTM)
-9.5042
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RCUS last week (0629-0703)?
Weekly Report · 2d ago
Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus
Simply Wall St · 3d ago
How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data
Simply Wall St · 4d ago
Arcus Biosciences announces publication on ARC-20 study research
TipRanks · 6d ago
Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney Cancer
Benzinga · 6d ago
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
Barchart · 07/01 10:00
Weekly Report: what happened at RCUS last week (0622-0626)?
Weekly Report · 06/29 09:56
Arcus Biosciences Opens New Front With First-In-Human Trial of AB102
TipRanks · 06/25 16:31
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.